Evidence map›Paper›PMID 24566709›Full record

Trial reportBone marrow transplantation2014

Impact of extracorporeal photopheresis on skin scores and quality of life in patients with steroid-refractory chronic GVHD.

F L Dignan, S Aguilar, J J Scarisbrick, B E Shaw, M N Potter, J Cavenagh, J F Apperley, A K Fielding, A Pagliuca, K Raj and 5 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 35 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. European dermatology forum - updated guidelines on the use of extracorporeal photopheresis 2020 - part 1.Journal of the European Academy of Dermatology and Venereology : JEADV · 2020
    Article
  6. Review
  7. Steroid Refractory Chronic Graft-Versus-Host Disease: Cost-Effectiveness Analysis.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

F L Dignan1] St John's Institute of Dermatology, St Thomas' Hospital, London, UK [2] Section of Haemato-oncology, The Royal Marsden Hospital, Sutton, UK [3] University College London, Cancer Institute, London, UK.
S AguilarSt John's Institute of Dermatology, St Thomas' Hospital, London, UK.
J J ScarisbrickDepartment of Dermatology, Queen Elizabeth Hospital, Birmingham, UK.
B E Shaw1] Section of Haemato-oncology, The Royal Marsden Hospital, Sutton, UK [2] University College London, Cancer Institute, London, UK.
M N PotterSection of Haemato-oncology, The Royal Marsden Hospital, Sutton, UK.
J CavenaghDepartment of Haematology, St Bartholomew's Hospital, London, UK.
J F ApperleyCentre for Haematology, Imperial College, London, UK.
A K FieldingDepartment of Haematology, University College London, London, UK.
A PagliucaDepartment of Haematological Medicine, King's College London Denmark Hill Campus, London, UK.
K RajDepartment of Haematological Medicine, King's College London Denmark Hill Campus, London, UK.
D I MarksDepartment of Haematology, University Hospitals Bristol NHS Foundation Trust, Bristol, UK.
A PeniketDepartment of Haematology, The Churchill Hospital, Oxford, UK.
C CrawleyCambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
M B KohDepartment of Haematology, St George's Hospital, London, UK.
F J ChildSt John's Institute of Dermatology, St Thomas' Hospital, London, UK.
St Thomas' Hospital · GBKing's College London · GBRoyal Marsden Hospital · GBCambridge University Hospitals NHS Foundation Trust · GBChurchill Hospital · GBImperial College London · GBQueen Elizabeth Hospital Birmingham · GBSt Bartholomew's Hospital · GBSt George's Hospital · GBUniversity College London · GBUniversity Hospitals Bristol NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are few prospective studies evaluating the role of extracorporeal photopheresis (ECP) in chronic GVHD (cGVHD) and only occasional reports of the effect of ECP on patients' quality of life (QoL). We report a single-centre prospective study of patients undergoing fortnightly ECP for moderate or severe cGVHD. Response was assessed after 6 months of treatment using NIH scoring criteria and reduction in immunosuppression. QoL assessments were undertaken at baseline and at 6 months using the chronic GVHD symptom scale (cGVHD SS) and dermatology life quality index (DLQI). An intention-to-treat analysis showed that 19/38 (50%) of patients had a complete or partial response. Twenty-seven out of 38 patients completed 6 months of ECP treatment and 70% (19/27) had a complete or partial response. Eighty per cent of patients who completed 6 months of ECP treatment had a reduction in immunosuppression dose. A subset of patients completed QoL questionnaires. Seventeen out of 18 patients (94%) showed an improvement in scores. The mean cGVHD SS and mean DLQI score were both significantly lower after 6 months of ECP (22 compared with 36, P=0.012 and 3.4 compared with 6.9, P=0.009, respectively). This study confirms that ECP can lead to objective clinical responses and, in addition, may lead to an improvement in QoL in cGVHD.

Indexed as

Quality of LifeAdolescentAdultAgedChronic DiseaseDrug ResistanceFemaleGraft vs Host DiseaseHumansImmunosuppressive AgentsImmunotherapyMaleMiddle AgedPhotopheresisProspective StudiesSkinImmunosuppressive AgentsSteroids

Identifiers

PMID24566709
OpenAlexW2008489836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.